Abstract
Glioblastoma (GBM) is an extremely aggressive, recurrent, and incurable tumor characterized by significant cellular and molecular heterogeneity, posing a challenge for advancements in its therapy and scientific research modeling. GBM is sustained by a subpopulation of glioblastoma stem cells (GSCs) responsible for promoting angiogenesis, invasion, and therapy resistance. Preclinical model…